Patent Grant
9308068
1. Technical Field
The present disclosure relates to an implant suitable for use in the prevention and/or treatment of hernias that may occur in the area of a stoma, particularly one formed in the abdominal wall.
2. Description of Related Art
Stomas are openings formed in a wall, for example the abdominal wall, for joining a hollow organ, for example the intestine, to the skin. Such an operation proves necessary, for example in cases of cancer of the rectum or Crohn's disease, to create an artificial anus for example, during which operation the diseased part of the intestine is resected and the healthy intestine is exteriorized at the skin. In this case, the stoma is formed in the abdominal wall.
After operations of this kind, hernias may develop around the stoma, that is to say in the area of the peristomal wall. A weakening of the wall around the stoma may therefore result in the appearance of a parastomal hernia. To treat these parastomal hernias, prostheses are implanted that are designed to strengthen the abdominal wall inside the patient, in the area of the stoma. The implantation of these prostheses can be intraperitoneal, that is to say within the actual abdominal wall, or retroperitoneal, resting against the abdominal wall.
Prostheses for treating parastomal hernias have been described in the document WO2004/071349. However, these prostheses are not entirely satisfactory, particularly since they are not adapted to all types of stomas that are formed, particularly indirect stomas.
The reason is that, for example in the case of the colon, several stoma configurations can be formed: the direct stoma, as shown in
There is therefore a need for a parastomal prosthesis able to protect the intestine and hollow organs and to effectively strengthen the abdominal wall regardless of the type of stoma that has been formed.
The present disclosure aims to meet this need by making available an implant that has specific surfaces able to protect the hollow organs, such as the intestine, regardless of the stoma that has been formed, and at the same time to effectively strengthen the abdominal wall.
The subject matter of the present disclosure is an implant for the prevention or treatment of a hernia formed in the abdominal wall in the proximity of a stoma of an organ, having a porous structure including a surface intended to face the abdominal cavity covered by a first film of anti-adhesive material, the porous structure including a first part intended to be in contact with the stoma organ and having a first thickness E1, and a second part having a second thickness E2 greater than the first thickness E1, the first part having a surface intended to face the abdominal wall covered by a second film of anti-adhesive material.
Thus, in the implant according to the disclosure, the first part of the porous structure, the part intended to be in contact with the stoma organ, for example in contact with the intestine, is covered by a film of anti-adhesive material on both of its surfaces. In one embodiment of the disclosure, the first and second films of anti-adhesive material are joined to form just one film, and the first part of the porous structure is totally enclosed within the film of anti-adhesive material. As will become clear from the explanations given later with reference to
In the present application, an “implant” is understood as a biocompatible medical device that can be implanted in the human or animal body.
Within the meaning of the present application, the word “porous” is understood as the characteristic according to which a structure has pores or meshes, pockets, holes or orifices, that are open and are distributed uniformly or irregularly and promote all cell colonization. The pores can be present in all types of configurations, for example as spheres, channels, hexagonal forms.
According to one embodiment of the disclosure, the porous structure includes a sponge, a fibrous matrix or a combination of a sponge and of a fibrous matrix. For example, the sponge can be obtained by lyophilization of a gel, with pores being created during the lyophilization. The fibrous matrix can be any arrangement of yarns or yarn portions creating pores between the yarns and/or yarn portions. For example, the fibrous matrix can be a textile, for example obtained by knitting or weaving or according to a technique for producing a nonwoven.
In one embodiment of the present disclosure, the porous structure, for example the sponge and/or the fibrous matrix, has pores with dimensions ranging from approximately 0.1 to approximately 3 mm.
In one embodiment of the present disclosure, the porous structure includes a textile. For example, the porous structure can be composed of a textile.
According to one embodiment of the present disclosure, the thickness E1 of the first part of the porous structure ranges from approximately 0.15 to 0.50 mm. A relatively small thickness of this kind allows the abdominal wall to be strengthened without any risk of damaging the stoma organ, for example the intestine, which is in contact with the implant.
The first part of the porous structure may be a textile in the form of a knit. This knit may be a two-dimensional knit, in embodiments a knit having a thickness less than or equal to about 5 times the mean diameter of the yarns from which it is made, for example knitted on a warp knitting machine or raschel machine with the aid of two guide bars forming a knit with two surfaces, the knit being free of sheets of connecting yarns between its two opposite surfaces.
When the first part of porous structure is a two-dimensional knit as defined above, the pores are formed by the empty spaces situated between the constituent yarns of the knit, for example the meshes.
The constituent yarns of the knit that form the first part of porous structure can be chosen from among yarns made of biocompatible materials, bioabsorbable materials, non-bioabsorbable materials and their mixtures.
In the present application, the word “bioabsorbable” is understood as the characteristic according to which a material is absorbed by the biological tissues and disappears in vivo at the end of a given period, which can vary for example from one day to several months, depending on the chemical nature of the material.
Thus, examples of bioabsorbable materials suitable for the yarns forming the first part of porous structure are polylactic acid (PLA), polysaccharides, polycaprolactones (PCL), polydioxanones (PDO), trimethylene carbonates (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHA), polyamides, polyethers, oxidized cellulose, polyglycolic acid (PGA), copolymers of these materials and their mixtures.
Examples of non-bioabsorbable materials suitable for the yarns forming the first part of porous structure are polypropylenes, polyesters such as polyethylene terephthalates, polyamides, polyvinylidene fluoride, and their mixtures.
The yarns forming the first part of porous structure of the implant can, for example, be chosen from among monofilament yarns, multifilament yarns and their combinations. The multifilament yarn count may vary from about 40 to about 110 dtex. The monofilament yarns may also have a diameter from about 0.06 to about 0.15 mm.
In one embodiment of the present disclosure, the yarns forming the first part of the porous structure are monofilament yarns. Such monofilament yarns may pose less risk of sepsis than do multifilament yarns. In one embodiment of the present disclosure, the monofilament yarns are of polyethylene terephthalate.
A monofilament yarn suitable for the first textile part of the implant according to the present disclosure is, for example, a monofilament yarn with a diameter of approximately 0.08 mm, of polyethylene terephthalate.
The porous structure of the implant according to the present disclosure includes a second part with a thickness E2 greater than the thickness E1 of the first part. The second part of the porous structure may be designed to act as a reinforcement of the abdominal wall.
Thus, the value of the thickness E2 of the second part of porous structure can vary depending on the value of the thickness E1 of the first part of the structure, the value of the thickness E2 of the second part of porous structure may be greater than that of the value of the thickness E1 of the first part of porous structure. The second part of the porous structure may have mechanical strength superior to that of the first part of porous structure. For example, the second thickness E2 of the second part of the porous structure can range from approximately 0.40 to 3.00 mm.
As will become clear from the description that follows, the surface of the layer of porous structure intended to be placed facing the abdominal cavity is covered by a film of anti-adhesive material which prevents the organs and other viscera of the abdominal cavity from attaching themselves to the implant. This surface will be referred to hereinafter as the closed surface of the implant. By contrast, the surface of the second part of porous structure intended to be placed facing the abdominal wall is not covered by a film of anti-adhesive material and remains open to all cell colonization at the time of implantation. This surface will be referred to hereinafter as the open surface of the second part of the porous structure. This surface of the second part of the porous structure is intended to be placed resting against the abdominal wall. To permit better fixing of the implant to the abdominal wall, the open surface of the second part of porous structure can include fastening means, for example self-fixing ones, inherent to this surface.
Thus, by virtue of its porous character and its thickness, the second part of the porous structure of the implant according to the disclosure is especially adapted to promote tissue growth via its open surface after implantation. The cells of the abdominal wall deeply colonize the second part of the porous structure by way of its open surface placed facing the abdominal wall.
In one embodiment of the present disclosure, the second part of the porous structure is a textile in the form of a three-dimensional knit, for example as described in applications WO99/06080 and WO99/05990, the disclosures of which are incorporated herein by this reference in their entirety. Within the meaning of the present application, the term “three-dimensional knit” is understood as an assembly or arrangement of monofilament or multifilament yarns or a combination of these, obtained by knitting and having two opposite surfaces that are separated by a thickness, in embodiments greater than or equal to about 0.50 mm, the thickness including connecting yarns and pores.
Such a three-dimensional knit can be knitted, for example, on a warp knitting machine or double-bed raschel machine with the aid of several guide bars forming a knit that includes two opposite surfaces and a spacer. In the present application, the word “spacer” is understood as the set or sets of yarns that connect the two surfaces of a three-dimensional knit to each other, thereby constituting the thickness of a knit, as is described in WO99/06080 or in WO99/05990.
Thus, in the case where the second part of the porous structure is a three-dimensional knit as described above, the knitting structure can define within the thickness of the knit a multiplicity of transverse channels or pockets that may or may not be mutually parallel. These pockets or channels can be interconnected and thus allow the colonizing cells to pass from one pocket or channel to another. A second part of the porous structure of this type promotes good tissue growth after implantation.
The yarns constituting the second part of the porous structure of the implant according to the present disclosure can be chosen from among yarns made of biocompatible materials, bioabsorbable materials, non-bioabsorbable materials and their mixtures, already listed above for the first part of the porous structure.
Thus, examples of bioabsorbable materials suitable for the yarns forming the second part of the porous structure are polylactic acid (PLA), polysaccharides, polycaprolactones (PCL), polydioxanones (PDO), trimethylene carbonates (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHA), polyamides, polyethers, oxidized cellulose, polyglycolic acid (PGA), copolymers of these materials and their mixtures.
Examples of non-bioabsorbable materials suitable for the yarns forming the second part of the porous structure are polypropylenes, polyesters such as polyethylene terephthalates, polyamides, polyvinylidene fluoride, and their mixtures.
The yarns forming the second part of the porous structure can, for example, be chosen from among monofilament yarns, multifilament yarns and their combinations. The multifilament yarn count may vary from about 40 to about 110 dtex. The monofilament yarns may have a diameter of from about 0.06 to about 0.15 mm.
In one embodiment of the present disclosure, the yarns forming the first part of the porous structure are monofilament yarns. Such monofilament yarns may pose less risk of sepsis than do multifilament yarns. For example, the monofilament yarns are of polyethylene terephthalate.
A monofilament yarn suitable for the second part of the porous structure of the implant according to the present disclosure is, for example, a monofilament yarn with a diameter of approximately 0.08 mm, of polyethylene terephthalate.
In one embodiment of the present disclosure, the second part of the porous structure has, on its open surface intended to face the abdominal wall, means of fastening the second part to the abdominal wall. These fastening means can be chosen from among elements that are integrally formed on the second textile part, such as loops and barbs, or from among elements joined to the surface of the second textile part, such as a rough covering, hooks, threads or clips fixed on the surface of the second textile part.
In one embodiment of the present disclosure, the fastening means are chosen from among loops, barbs and their mixtures. In such a case, the loops and barbs can be obtained from yarns or portions of yarns that are woven and/or knitted directly for example, with the three-dimensional knit forming the second part of the porous structure. For example, in order to obtain barbs, it is possible to use hot-melt yarns such as are described in the application WO01/81667, the contents of which are herein incorporated by reference in its entirety.
In the embodiment of the present disclosure in which the first part of the porous structure is in the form of a two-dimensional knit and the second part of the porous structure is in the from of a three-dimensional knit, the two knits, i.e. two-dimensional and three-dimensional, can be manufactured separately then joined together by at least one seam, for example, in order to form the layer of porous structure of the implant.
In another embodiment, the two-dimensional knit and the three-dimensional knit are knitted together on the same knitting machine and constitute a textile made in one piece, for example by using supplementary guide bars for the three-dimensional knit and/or different yarn runs for producing each of the two knits. In such an embodiment of the present disclosure, the porous structure layer of the implant according to the disclosure is composed of a textile formed in one piece, the textile having a two-dimensional zone, corresponding to the first part of the porous structure, and one or more three-dimensional zones, corresponding to the second part of the porous structure. In such an embodiment, it is possible to form a selvage at the passage from a two-dimensional zone to a three-dimensional zone with a view to forming a smooth connection between the two parts, such that the difference in thickness between the two parts does not form a step that could damage the biological tissue situated in the proximity of the implant.
The layer of porous structure of the implant according to the present disclosure is covered, on its second surface intended to face the abdominal cavity, by a first film of anti-adhesive material. Moreover, the first part of the porous structure is covered, on its surface intended to face the abdominal wall, by a second film of anti-adhesive material.
Within the meaning of the present application, the term “anti-adhesive material” is understood as a smooth and non-porous biocompatible material that prevents the organs and other viscera of the abdominal cavity from attaching themselves to the implant.
The anti-adhesive material forming the first film can be identical to or different from the material forming the second film.
In one embodiment of the present disclosure, the anti-adhesive material constituting the first and/or second film(s) is chosen from among bioabsorbable materials, non-bioabsorbable materials and their mixtures.
In one embodiment of the present disclosure, the bioabsorbable materials suitable for the first and/or second film(s) of anti-adhesive material are chosen from among collagens, oxidized celluloses, polyarylates, trimethylene carbonates, caprolactones, dioxanones, glycolic acid, lactic acid, glycolides, lactides, polysaccharides, for example chitosans, polyglucuronic acids, hylauronic acids, dextrans and their mixtures.
In one embodiment of the present disclosure, the non-bioabsorbable materials suitable for the first and/or second film of anti-adhesive material are chosen from among polytetrafluoroethylene, polyethylene glycols, polysiloxanes, polyurethanes, stainless steels, derivatives of precious metals and their mixtures.
In one embodiment of the present disclosure, the material constituting the first and/or second film(s) of anti-adhesive material is a hydrophilic bioabsorbable material, which may be chosen from the group formed by collagens, polysaccharides and their mixtures. Of the collagens that can be used according to the present disclosure, the following may be mentioned:
1) collagen whose helical structure is at least partially denatured by heat, without hydrolytic degradation, and whose method of preparation is described in WO99/06080,
2) native collagen, not heated, filmed with or without glycerol, crosslinked by gamma irradiation or by other chemical or physical means,
3) and/or their mixtures.
Of the polysaccharides that can be used as absorbable hydrophilic material according to the present disclosure, the following may be mentioned: oxidized cellulose, hylauronic acid, starch, chitosan, crosslinked dextrans and/or their mixtures. All these materials are within the purview of persons skilled in the art. An oxidized cellulose suitable for the present disclosure is the product sold under the brand name “Interceed®” by Ethicon. A hyaluronic acid suitable for the present disclosure is the product sold under the brand name “Hyalobarrier®” by Fidia Advanced Biopolymers, or the product sold under the brand name “Seprafilm®” by Genzyme.
In one embodiment of the present disclosure, the first film and the second film form a single and unique film, the first film then completely coating the first part of the porous structure and thus covering this porous structure part both on its surface intended to face the abdominal cavity and also on its surface intended to face the abdominal wall. Thus, the first part of the porous structure is totally enclosed in the film of anti-adhesive material before implantation and at the moment of implantation.
Thus, at the moment of implantation, and whatever the embodiment of the present disclosure, the two surfaces of the first part of the porous structure are occluded by a continuous film of anti-adhesive material.
The first part of the porous structure of the implant according to the present disclosure, regardless of whether it is totally coated by the first film of anti-adhesive material or whether each of its surfaces are covered, one by the first film of anti-adhesive material, the other by the second film of anti-adhesive material, is thus protected at least during the initial phase of cicatrization, i.e. is not exposed to the inflammatory cells such as granulocytes, monocytes, macrophages, or the multinucleated giant cells that are generally activated by the surgical procedure. Nor is it exposed to the bacteria that may be present. The reason for this is that, at least during the initial phase of cicatrization, which may last approximately 5 to 10 days, only the film or films of anti-adhesive material are accessible to the various factors such as proteins, enzymes, cytokines or inflammatory cells, in the first textile part.
In the case where the film or films of anti-adhesive material are made of non-absorbable materials, they thus protect the first part of porous structure before and after implantation, throughout the period of implantation of the implant.
Furthermore, by virtue of the film or films of anti-adhesive material, the surrounding fragile tissues, such as the hollow viscera for example, are protected in particular from the formation of severe postsurgical fibrous adhesions.
In the case where the anti-adhesive material includes a bioabsorbable material, in embodiments a bioabsorbable material may be chosen that is not absorbed until after a few days, such that the film of anti-adhesive material can perform its function of protecting the stoma organ, for example the intestine, and the hollow organs during the days following the operation, and until the cellular recolonization of the implant in turn protects the fragile organs.
The thickness of the first anti-adhesive film may be less than the thickness E2 of the second part of the porous structure. In fact, the film of anti-adhesive material may not occlude the open surface of the second part of the porous structure, so as to permit cellular recolonization of the second part of the porous structure after implantation.
The first film of anti-adhesive material may be continuous, smooth and non-porous, covering the whole surface of the porous structure intended to be placed facing the abdominal cavity. In one embodiment, the first film of anti-adhesive material extends past the edges of the layer of porous structure. Thus, the implant is protected from contact with the viscera. The first film of anti-adhesive material can, for example, extend past the edges of the layer of porous structure by a distance ranging from about 3 to about 10 millimeters.
The first film of anti-adhesive material may be joined to the surface of the layer of porous structure intended to be placed facing the abdominal cavity by means of surface penetration, keeping open the porosity on the opposite surface of the second part of the porous structure, that is to say the open surface, intended to be placed facing the abdominal wall.
The implant according to the present disclosure can be used via the laparoscopic route. If necessary, for example when the first and second films of anti-adhesive material are made of dried collagen, the implant may be rehydrated at the time of use, in order to make it flexible and easier to use.
The implant according to the present disclosure can, for example, be prepared according to the following method:
a) a textile is prepared that has two-dimensional zones and three-dimensional zones, as has been described above,
b) a solution of an anti-adhesive material is prepared,
c) the solution obtained at b) is poured into a mould,
d) the textile is then applied to the solution, the surface of the textile intended to face the abdominal cavity being placed on the solution in such a way that the solution impregnates the two-dimensional zones of the textile completely,
e) it is left to dry.
With such a method it is possible to obtain an implant according to the present disclosure in which the first film and the second film form a single and unique film.
Alternatively, step d) is replaced by step d′) in which the solution of anti-adhesive material only superficially impregnates a single surface of the two-dimensional zones, thereby forming the first film. The procedure is then supplemented by an additional step in which the opposite surface of the two-dimensional zones is impregnated by the same solution of anti-adhesive material or by another solution of another anti-adhesive material in order to form the second film.
Methods of covering/coating that can be used according to the present disclosure are described in documents WO99/06080 and WO2004/043294, the disclosure of which are incorporated herein by this reference in their entirety.
The implant according to the present disclosure can have any shape adapted to the anatomy of the patient and/or to the surgical technique envisaged. For example, the shape of the implant can be round, oval, square or rectangular.
In one embodiment, the implant has a generally elongate shape, for example oval or rectangular. For example, the length of the implant may be from about 12 to about 30 cm and its width may be from about 10 to about 20 cm.
In another embodiment, the implant has a generally round shape. For example, the diameter of the implant may be from about 5 to about 20 cm.
In one embodiment of the present disclosure, the first part of the porous structure has the form of a central strip, and, for example, the width of the central strip may be from about 2 to about 10 cm.
In another embodiment of the present disclosure, the first part of the porous structure has the form of a disc, and, for example, the diameter of the disc may be from about 2 to about 10 cm.
In one embodiment of the present disclosure, at least one orifice is formed at the centre of the first part of the porous structure in order to provide a passage for the stoma organ, for example the intestine, during implantation of the implant. Alternatively, at least one orifice is formed within the first part of the porous structure, the orifice being offset relative to the centre of the implant. For certain types of surgery, for example ureterostomies, the implant can have two orifices. In one embodiment of the present disclosure, the orifice or orifices can be connected to an edge of the implant by way of a slit. For example, the dimensions of the orifices may be from about 0.5 to about 8 cm. The orifice or orifices can be offset relative to the centre of the implant.
The principles of the present disclosure, and variants thereof, will become evident from the following detailed description and from the attached drawings, in which:
Referring to
As seen in
The implant 10 shown in
In one example not shown, the implant has a generally round shape. Its diameter may then be from about 5 to about 20 cm, for example.
Referring to
Thus, as seen in
By contrast, in regards to the second part 15 of the textile, its first surface 12, intended to be placed facing the abdominal wall, is not covered by film 16 of anti-adhesive material. This surface 12 will be referred to hereinbelow as the open surface of the second part 15 of the textile. By contrast, the second surface 13 intended to be placed facing the abdominal cavity, is covered by film 16 of anti-adhesive material. This surface 13 will be referred to hereinbelow as the closed surface of the second part of the textile. Thus, the film 16 of anti-adhesive material penetrates only superficially into the second part 15 of the textile, in the area of its closed surface 13, leaving open the porosity of the first open surface 12 of the second textile part 15.
Bar A: 4-4-5-4/4-4-4-3/3-3-2-1/1-1-0-1/1-1-1-2/2-2-3-4//
Bar B: 1-1-0-1/1-1-1-2/2-2-3-4/4-4-5-4/4-4-4-3/3-3-2-1//
The yarn used may be a monofilament yarn of polyethylene terephthalate, having a diameter of about 0.08 mm and a titre of about 69 dtex. The knit thus formed includes two opposite surfaces but is free of connecting sheets between its two opposite surfaces. It is a two-dimensional knit according to the present application.
The thickness of the first part of the textile formed from such a knit is approximately 0.25 mm.
In the example shown, the knitting used for the first part of the textile creates pores, in embodiments with dimensions that can range from about 0.1 to about 3 mm, in embodiments from about 1.5 to about 2 mm. At the moment of implantation, these pores are not visible, nor are they accessible to tissue colonization, because the whole of the first part of the textile is confined in the film 16 of anti-adhesive material. However, after a few days, as the film of anti-adhesive material is absorbed and disappears after performing its function of limiting and/or avoiding formation of adhesions during the first 10 days following the implantation operation, the pores of the first part 14 of the textile become accessible to tissue colonization. When a yarn of polyethylene terephthalate is used for producing the two-dimensional knit, this knit is non-bioabsorbable and remains permanently at the implantation site.
In another embodiment of the present disclosure, the first part 14 of the textile is made of a bioabsorbable material that is absorbed more slowly than the bioabsorbable material constituting the film 16 of anti-adhesive material.
As is shown in
Thus, as will be seen clearly from
The second part 15 of the textile, of which the thickness is greater than that of the first part 14 of the textile, can be a knit which is obtained on a warp knitting machine or double-bed raschel machine and which has two opposite surfaces connected to each other by connecting yarns, that is to say a three-dimensional knit according to the present application. For example, a first surface of the knit is produced with the two guide bars A and B already mentioned above for producing the first part 14 of textile, these being threaded identically and with the same charts as above. The second surface of the knit is produced with two supplementary guide bars D and E, threaded with one guide full, one guide empty, using the knitting structure shown in
Bar D: 0-1-1-1/1-2-2-2/3-4-4-4/5-4-4-4/4-3-3-3/2-1-1-1//
Bar E: 5-4-4-4/4-3-3-3/2-1-1-1/0-1-1-1/1-2-2-2/3-4-4-4//
The connection of the two surfaces can be effected, for example, by hooking one loop in two, or in three, or in four, or in five, or in six of one of the bars D or E, whose knitting structure will be adapted. For example, in one embodiment of the present disclosure, the connection of the two surfaces is effected by hooking one loop in three of the bar E, which thus becomes bar E′, with the knitting structure shown in
Bar E′: 5-4-3-4/4-3-3-3/2-1-1-1/0-1-2-1/1-2-2-2/3-4-4-4//
In another embodiment, the connection of the two surfaces can be effected with the aid of a fifth guide bar C, with the knitting structure shown in
Bar C: 1-0-1-0/1-1-1-1/1-1-1-1//
Thus, when the first part 14 of the textile is in the form of a central strip separating two lateral strips of the second part 15 of the textile, as is shown in
With the guide bars A, B, D and E′ described above:
the whole of the first surface 13 of the textile 11 is produced with the two guide bars A and B,
along a first length, corresponding to the first lateral strip of the second part 15 of the textile, the guide bars D and E′ are threaded one guide full, one guide empty, in order to produce the second surface of the three-dimensional knit forming the second part 15 of the textile,
then, along the length corresponding to the width of the central strip of the first part 14 of the textile, the guide bars D and E′ are left empty in order to form the two-dimensional knit,
finally, along a length corresponding to the second lateral strip of the second part 15 of the textile, the guide bars D and E′ are again threaded one guide full, one guide empty, in order to produce the second surface of the three-dimensional knit forming the second part 15 of the textile.
In such a case, the optional fifth guide bar C is threaded only in the zones of the three-dimensional knit.
Finally, in order to obtain a smooth join between the three-dimensional knit forming the second part 15 of the textile and the two-dimensional knit forming the first part 14 of the textile, it is possible to use, still on the same knitting machine, a supplementary guide bar F in order to finish the edges of the three-dimensional knits, threaded in the area of these edges, according to the knitting structure shown in
Bar F: 1-0-1-1/1-2-1-1//
A monofilament yarn may be chosen to produce the second part 15 of the textile. This is because multifilament yarns may pose greater risks of bacteria developing in the interstices present between the various filaments of the yarn.
The yarn used may be a monofilament yarn of polyethylene terephthalate, with a diameter of approximately 0.08 mm and titre of approximately 69 dtex.
The thickness of the second part 15 of the textile, produced in the form of the three-dimensional knit described above, is approximately 1.50 mm.
As will be seen from
The superficial covering of the surface of the second part 15 of textile intended to be placed facing the abdominal cavity can be carried out using any method within the purview of a person skilled in the art, for example using the method described in the application WO99/06080.
The material used for the film 16 of anti-adhesive material can, for example, be collagen prepared in the manner described in the application WO99/06080.
The film 16 of anti-adhesive material may be applied to the surface of the textile 11 intended to be placed facing the abdominal cavity, in the following way:
The solution of collagen is poured into a mould having the external dimensions desired for the film. The textile produced above is then applied to this solution, at the centre of the mould, the surface to be covered being placed on the solution of collagen. The solution of collagen then penetrates into the textile by capillary force, completely coating the first part of textile and covering the latter on the two opposite surfaces of the two-dimensional knit forming it, and penetrating only by a small distance into the thickness of the second part of textile, thus creating a superficial film for this three-dimensional part. Once the collagen has dried, the film is cut around the textile using a scalpel.
Alternatively, the covering/coating method described in WO2004/043294 can be used.
In another embodiment not shown here, the film 16 only superficially covers the surface of the first part of the textile, intended to be placed facing the abdominal cavity, and does not encompass the two opposite surfaces of this first part of the textile. In such a case, the surface of the first part of the textile intended to be placed facing the abdominal wall is covered with a second film of anti-adhesive material. Thus, each of the two opposite surfaces of the first part of the textile is covered by a smooth and continuous film of anti-adhesive material. Covering methods that can be used to form this second film are also described in WO2004/043294.
In one embodiment not shown here, the orifice 17 is offset relative to the centre of the implant 10. It is also possible to have several orifices, depending on the surgery envisaged.
Thus, in
It is possible to fix the implant 10 to the abdominal wall 7 using staples or sutures. In addition, or alternatively, the open surface of the second part 15 of the textile can intrinsically include barbs or loops, which will facilitate its natural attachment to the abdominal wall. Such an affixing knit is described in the application WO01/81667.
Finally, the second surface of the textile, completely covered by film 16 of anti-adhesive material, is situated facing the abdominal cavity 8. Thus, the hollow and fragile organs, the viscera, are not damaged by the implant.
As will be seen from these two figures, the part 3c of the colon faces and is able to come into contact with the first part 14 of the textile covered on its two opposite surfaces by the film 16 of anti-adhesive material. Thus, neither the part 3c of the colon, situated between the implant 10 and the abdominal wall 7, nor the part 3d of the colon corresponding to the second length of the bend and able to lie under the implant 10 in the area of the abdominal cavity 8, risks being damaged by the implant 10. This is because the parts 3c and 3d of the colon 3 are each facing a surface of the first part 14 of textile covered by a film 16 of anti-adhesive material. Moreover, the relatively small thickness E1 of this first part 14 of textile permits flexible and atraumatic support of the colon 3.
In an indirect stoma of this kind, the implant 10 may act like a hammock for the part 3c of the colon 3, and the implant 10 can be fixed to the abdominal wall 7 via the open surface of the second part 15 of the textile placed facing the abdominal wall 7.
The present disclosure also relates to a method for treatment or prevention of a hernia in the proximity of a stoma formed in the skin, including the step of implanting an implant of the type described above in the area of the stoma. In one embodiment of the present disclosure, the implant is fixed to the abdominal wall. The implant described above can be implanted by open surgery or by laparoscopy.
The implant according to the present disclosure is used in particular in the treatment of parastomal hernias. It is able to support and/or protect the organs that are to be treated, such as the colon or ureters, without damaging them, while at the same time effectively strengthening the wall in which the stoma is formed, such as the abdominal wall, irrespective of the type of stoma formed, i.e. direct stoma or indirect stoma.
This application claims the benefit of U.S. Provisional Application No. 61/005,131, filed Dec. 3, 2007.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1187158 | McGinley | Jun 1916 | A |
| 3364200 | Ashton et al. | Nov 1961 | A |
| 3118294 | Van Laethem | Jan 1964 | A |
| 3124136 | Usher | Mar 1964 | A |
| 3272204 | Artandi et al. | Sep 1966 | A |
| 3276448 | Kronenthal et al. | Oct 1966 | A |
| 3320649 | Naimer | May 1967 | A |
| 3570482 | Emoto et al. | Mar 1971 | A |
| 4006747 | Kronenthal et al. | Feb 1977 | A |
| 4060081 | Yannas et al. | Nov 1977 | A |
| 4173131 | Pendergrass et al. | Nov 1979 | A |
| 4193137 | Heck | Mar 1980 | A |
| 4248064 | Odham | Feb 1981 | A |
| 4294241 | Miyata | Oct 1981 | A |
| 4307717 | Hymes et al. | Dec 1981 | A |
| 4338800 | Matsuda | Jul 1982 | A |
| 4476697 | Schäfer et al. | Oct 1984 | A |
| 4487865 | Balazs et al. | Dec 1984 | A |
| 4500676 | Balazs et al. | Feb 1985 | A |
| 4511653 | Play et al. | Apr 1985 | A |
| 4527404 | Nakagaki et al. | Jul 1985 | A |
| 4591501 | Cioca | May 1986 | A |
| 4597762 | Walter et al. | Jul 1986 | A |
| 4603695 | Ikada et al. | Aug 1986 | A |
| 4631932 | Sommers | Dec 1986 | A |
| 4670014 | Huc et al. | Jun 1987 | A |
| 4709562 | Matsuda | Dec 1987 | A |
| 4748078 | Doi et al. | May 1988 | A |
| 4759354 | Quarfoot | Jul 1988 | A |
| 4769038 | Bendavid et al. | Sep 1988 | A |
| 4796603 | Dahlke et al. | Jan 1989 | A |
| 4813942 | Alvarez | Mar 1989 | A |
| 4841962 | Berg et al. | Jun 1989 | A |
| 4854316 | Davis | Aug 1989 | A |
| 4925294 | Geshwind et al. | May 1990 | A |
| 4931546 | Tardy et al. | Jun 1990 | A |
| 4942875 | Hlavacek et al. | Jul 1990 | A |
| 4948540 | Nigam | Aug 1990 | A |
| 4950483 | Ksander et al. | Aug 1990 | A |
| 4970298 | Silver et al. | Nov 1990 | A |
| 5002551 | Linsky et al. | Mar 1991 | A |
| 5147374 | Fernandez | Sep 1992 | A |
| 5162430 | Rhee et al. | Nov 1992 | A |
| 5171273 | Silver et al. | Dec 1992 | A |
| 5176692 | Wilk et al. | Jan 1993 | A |
| 5192301 | Kamiya et al. | Mar 1993 | A |
| 5196185 | Silver et al. | Mar 1993 | A |
| 5201764 | Kelman et al. | Apr 1993 | A |
| 5206028 | Li | Apr 1993 | A |
| 5217493 | Raad et al. | Jun 1993 | A |
| 5254133 | Seid | Oct 1993 | A |
| 5256418 | Kemp et al. | Oct 1993 | A |
| 5263983 | Yoshizato et al. | Nov 1993 | A |
| 5304595 | Rhee et al. | Apr 1994 | A |
| 5306500 | Rhee et al. | Apr 1994 | A |
| 5324775 | Rhee et al. | Jun 1994 | A |
| 5328955 | Rhee et al. | Jul 1994 | A |
| 5334527 | Brysk | Aug 1994 | A |
| 5339657 | McMurray | Aug 1994 | A |
| 5350583 | Yoshizato et al. | Sep 1994 | A |
| 5356432 | Rutkow et al. | Oct 1994 | A |
| 5368549 | McVicker | Nov 1994 | A |
| 5376375 | Rhee et al. | Dec 1994 | A |
| 5376376 | Li | Dec 1994 | A |
| 5397331 | Himpens et al. | Mar 1995 | A |
| 5399361 | Song et al. | Mar 1995 | A |
| 5413791 | Rhee et al. | May 1995 | A |
| 5425740 | Hutchinson, Jr. | Jun 1995 | A |
| 5428022 | Palefsky et al. | Jun 1995 | A |
| 5433996 | Kranzler et al. | Jul 1995 | A |
| 5441491 | Verschoor et al. | Aug 1995 | A |
| 5441508 | Gazielly et al. | Aug 1995 | A |
| 5456693 | Conston et al. | Oct 1995 | A |
| 5456711 | Hudson | Oct 1995 | A |
| 5466462 | Rosenthal et al. | Nov 1995 | A |
| 5480644 | Freed | Jan 1996 | A |
| 5487895 | Dapper et al. | Jan 1996 | A |
| 5490984 | Freed | Feb 1996 | A |
| 5512291 | Li | Apr 1996 | A |
| 5512301 | Song et al. | Apr 1996 | A |
| 5514181 | Light et al. | May 1996 | A |
| 5522840 | Krajicek | Jun 1996 | A |
| 5523348 | Rhee et al. | Jun 1996 | A |
| 5536656 | Kemp et al. | Jul 1996 | A |
| 5543441 | Rhee et al. | Aug 1996 | A |
| 5565210 | Rosenthal et al. | Oct 1996 | A |
| 5567806 | Abdul-Malak et al. | Oct 1996 | A |
| 5569273 | Titone et al. | Oct 1996 | A |
| RE35399 | Eisenberg | Dec 1996 | E |
| 5593441 | Lichtenstein et al. | Jan 1997 | A |
| 5595621 | Light et al. | Jan 1997 | A |
| 5601571 | Moss | Feb 1997 | A |
| 5607590 | Shimizu | Mar 1997 | A |
| 5614587 | Rhee et al. | Mar 1997 | A |
| 5618551 | Tardy et al. | Apr 1997 | A |
| 5634931 | Kugel | Jun 1997 | A |
| 5639796 | Lee | Jun 1997 | A |
| 5665391 | Lea | Sep 1997 | A |
| 5667839 | Berg | Sep 1997 | A |
| 5681568 | Goldin et al. | Oct 1997 | A |
| 5686115 | Vournakis et al. | Nov 1997 | A |
| 5690675 | Sawyer et al. | Nov 1997 | A |
| 5695525 | Mulhauser et al. | Dec 1997 | A |
| 5697978 | Sgro | Dec 1997 | A |
| 5700476 | Rosenthal et al. | Dec 1997 | A |
| 5700477 | Rosenthal et al. | Dec 1997 | A |
| 5709934 | Bell et al. | Jan 1998 | A |
| 5716409 | Debbas | Feb 1998 | A |
| 5720981 | Eisinger | Feb 1998 | A |
| 5732572 | Litton | Mar 1998 | A |
| 5749895 | Sawyer et al. | May 1998 | A |
| 5752974 | Rhee et al. | May 1998 | A |
| 5766246 | Mulhauser et al. | Jun 1998 | A |
| 5766631 | Arnold | Jun 1998 | A |
| 5769864 | Kugel | Jun 1998 | A |
| 5771716 | Schlussel | Jun 1998 | A |
| 5785983 | Furlan et al. | Jul 1998 | A |
| 5800541 | Rhee et al. | Sep 1998 | A |
| 5814328 | Gunasekaran | Sep 1998 | A |
| 5833705 | Ken et al. | Nov 1998 | A |
| 5840011 | Landgrebe et al. | Nov 1998 | A |
| 5861034 | Taira et al. | Jan 1999 | A |
| 5863984 | Doillon et al. | Jan 1999 | A |
| 5869080 | McGregor et al. | Feb 1999 | A |
| 5871767 | Dionne et al. | Feb 1999 | A |
| 5876444 | Lai | Mar 1999 | A |
| 5891558 | Bell et al. | Apr 1999 | A |
| 5899909 | Claren et al. | May 1999 | A |
| 5906937 | Sugiyama et al. | May 1999 | A |
| 5910149 | Kuzmak | Jun 1999 | A |
| 5911731 | Pham et al. | Jun 1999 | A |
| 5916225 | Kugel | Jun 1999 | A |
| 5919232 | Chaffringeon et al. | Jul 1999 | A |
| 5919233 | Knopf et al. | Jul 1999 | A |
| 5922026 | Chin | Jul 1999 | A |
| 5931165 | Reich et al. | Aug 1999 | A |
| 5942278 | Hagedorn et al. | Aug 1999 | A |
| 5962136 | Dewez et al. | Oct 1999 | A |
| 5972022 | Huxel | Oct 1999 | A |
| RE36370 | Li | Nov 1999 | E |
| 5993844 | Abraham et al. | Nov 1999 | A |
| 5994325 | Roufa et al. | Nov 1999 | A |
| 5997895 | Narotam et al. | Dec 1999 | A |
| 6001895 | Harvey et al. | Dec 1999 | A |
| 6008292 | Lee et al. | Dec 1999 | A |
| 6015844 | Harvey et al. | Jan 2000 | A |
| 6039686 | Kovac | Mar 2000 | A |
| 6042534 | Gellman et al. | Mar 2000 | A |
| 6042592 | Schmitt | Mar 2000 | A |
| 6043089 | Sugiyama et al. | Mar 2000 | A |
| 6051425 | Morota et al. | Apr 2000 | A |
| 6056688 | Benderev et al. | May 2000 | A |
| 6056970 | Greenawalt et al. | May 2000 | A |
| 6057148 | Sugiyama et al. | May 2000 | A |
| 6063396 | Kelleher | May 2000 | A |
| 6066776 | Goodwin et al. | May 2000 | A |
| 6066777 | Benchetrit | May 2000 | A |
| 6071292 | Makower et al. | Jun 2000 | A |
| 6077281 | Das | Jun 2000 | A |
| 6080194 | Pachence et al. | Jun 2000 | A |
| 6083522 | Chu et al. | Jul 2000 | A |
| 6120539 | Eldridge et al. | Sep 2000 | A |
| 6132765 | DiCosmo et al. | Oct 2000 | A |
| 6143037 | Goldstein et al. | Nov 2000 | A |
| 6153292 | Bell et al. | Nov 2000 | A |
| 6165488 | Tardy et al. | Dec 2000 | A |
| 6171318 | Kugel et al. | Jan 2001 | B1 |
| 6174320 | Kugel et al. | Jan 2001 | B1 |
| 6176863 | Kugel et al. | Jan 2001 | B1 |
| 6179872 | Bell et al. | Jan 2001 | B1 |
| 6197325 | MacPhee et al. | Mar 2001 | B1 |
| 6197934 | DeVore et al. | Mar 2001 | B1 |
| 6197935 | Doillon et al. | Mar 2001 | B1 |
| 6210439 | Firmin et al. | Apr 2001 | B1 |
| 6221109 | Geistlich et al. | Apr 2001 | B1 |
| 6224616 | Kugel | May 2001 | B1 |
| 6241768 | Agarwal et al. | Jun 2001 | B1 |
| 6258124 | Darois et al. | Jul 2001 | B1 |
| 6262332 | Ketharanathan | Jul 2001 | B1 |
| 6264702 | Ory et al. | Jul 2001 | B1 |
| 6267772 | Mulhauser et al. | Jul 2001 | B1 |
| 6277397 | Shimizu | Aug 2001 | B1 |
| 6280453 | Kugel et al. | Aug 2001 | B1 |
| 6287316 | Agarwal et al. | Sep 2001 | B1 |
| 6290708 | Kugel et al. | Sep 2001 | B1 |
| 6306424 | Vyakarnam et al. | Oct 2001 | B1 |
| 6312474 | Francis et al. | Nov 2001 | B1 |
| 6328686 | Kovac | Dec 2001 | B1 |
| 6334872 | Termin et al. | Jan 2002 | B1 |
| 6383201 | Dong | May 2002 | B1 |
| 6391333 | Li et al. | May 2002 | B1 |
| 6391939 | Tayot et al. | May 2002 | B2 |
| 6408656 | Ory et al. | Jun 2002 | B1 |
| 6410044 | Chudzik et al. | Jun 2002 | B1 |
| 6413742 | Olsen et al. | Jul 2002 | B1 |
| 6428978 | Olsen et al. | Aug 2002 | B1 |
| 6436030 | Rehil | Aug 2002 | B2 |
| 6440167 | Shimizu | Aug 2002 | B2 |
| 6443964 | Ory et al. | Sep 2002 | B1 |
| 6447551 | Goldmann | Sep 2002 | B1 |
| 6447802 | Sessions et al. | Sep 2002 | B2 |
| 6448378 | DeVore et al. | Sep 2002 | B2 |
| 6451032 | Ory et al. | Sep 2002 | B1 |
| 6451301 | Sessions et al. | Sep 2002 | B1 |
| 6454787 | Maddalo et al. | Sep 2002 | B1 |
| 6477865 | Matsumoto | Nov 2002 | B1 |
| 6479072 | Morgan et al. | Nov 2002 | B1 |
| 6500464 | Ceres et al. | Dec 2002 | B2 |
| 6509031 | Miller et al. | Jan 2003 | B1 |
| 6511958 | Atkinson et al. | Jan 2003 | B1 |
| 6514286 | Leatherbury et al. | Feb 2003 | B1 |
| 6514514 | Atkinson et al. | Feb 2003 | B1 |
| 6540773 | Dong | Apr 2003 | B2 |
| 6541023 | Andre et al. | Apr 2003 | B1 |
| 6548077 | Gunasekaran | Apr 2003 | B1 |
| 6554855 | Dong | Apr 2003 | B1 |
| 6559119 | Burgess et al. | May 2003 | B1 |
| 6566345 | Miller et al. | May 2003 | B2 |
| 6575988 | Rousseau | Jun 2003 | B2 |
| 6576019 | Atala | Jun 2003 | B1 |
| 6596002 | Therin et al. | Jul 2003 | B2 |
| 6596304 | Bayon et al. | Jul 2003 | B1 |
| 6599323 | Melican et al. | Jul 2003 | B2 |
| 6599524 | Li et al. | Jul 2003 | B2 |
| 6599690 | Abraham et al. | Jul 2003 | B1 |
| 6613348 | Jain | Sep 2003 | B1 |
| 6623963 | Müller et al. | Sep 2003 | B1 |
| 6630414 | Matsumoto | Oct 2003 | B1 |
| 6638284 | Rousseau et al. | Oct 2003 | B1 |
| 6652594 | Francis et al. | Nov 2003 | B2 |
| 6653450 | Berg et al. | Nov 2003 | B1 |
| 6656206 | Corcoran et al. | Dec 2003 | B2 |
| 6660280 | Allard et al. | Dec 2003 | B1 |
| 6669735 | Pelissier | Dec 2003 | B1 |
| 6682760 | Noff et al. | Jan 2004 | B2 |
| 6685714 | Rousseau | Feb 2004 | B2 |
| 6706684 | Bayon et al. | Mar 2004 | B1 |
| 6706690 | Reich et al. | Mar 2004 | B2 |
| 6719795 | Cornwall et al. | Apr 2004 | B1 |
| 6723335 | Moehlenbruck et al. | Apr 2004 | B1 |
| 6730299 | Tayot et al. | May 2004 | B1 |
| 6743435 | DeVore et al. | Jun 2004 | B2 |
| 6755868 | Rousseau | Jun 2004 | B2 |
| 6773723 | Spiro et al. | Aug 2004 | B1 |
| 6790213 | Cherok et al. | Sep 2004 | B2 |
| 6790454 | Abdul Malak et al. | Sep 2004 | B1 |
| 6800082 | Rousseau | Oct 2004 | B2 |
| 6833408 | Sehl et al. | Dec 2004 | B2 |
| 6835336 | Watt | Dec 2004 | B2 |
| 6852330 | Bowman et al. | Feb 2005 | B2 |
| 6869938 | Schwartz et al. | Mar 2005 | B1 |
| 6893653 | Abraham et al. | May 2005 | B2 |
| 6896904 | Spiro et al. | May 2005 | B2 |
| 6936276 | Spiro et al. | Aug 2005 | B2 |
| 6939562 | Spiro et al. | Sep 2005 | B2 |
| 6949625 | Tayot | Sep 2005 | B2 |
| 6966918 | Schuldt-Hempe | Nov 2005 | B1 |
| 6971252 | Therin et al. | Dec 2005 | B2 |
| 6974679 | Andre et al. | Dec 2005 | B2 |
| 6974862 | Ringeisen et al. | Dec 2005 | B2 |
| 6977231 | Matsuda | Dec 2005 | B1 |
| 6988386 | Okawa et al. | Jan 2006 | B1 |
| 7025063 | Snitkin et al. | Apr 2006 | B2 |
| 7041868 | Greene et al. | May 2006 | B2 |
| RE39172 | Bayon et al. | Jul 2006 | E |
| 7098315 | Schaufler | Aug 2006 | B2 |
| 7175852 | Simmoteit et al. | Feb 2007 | B2 |
| 7192604 | Brown et al. | Mar 2007 | B2 |
| 7207962 | Anand et al. | Apr 2007 | B2 |
| 7214765 | Ringeisen et al. | May 2007 | B2 |
| 7226611 | Yura et al. | Jun 2007 | B2 |
| 7229453 | Anderson et al. | Jun 2007 | B2 |
| 7594921 | Browning | Sep 2009 | B2 |
| 7670380 | Cauthen, III | Mar 2010 | B2 |
| 20010008930 | Tayot et al. | Jul 2001 | A1 |
| 20020095218 | Carr, Jr. et al. | Jul 2002 | A1 |
| 20020116070 | Amara et al. | Aug 2002 | A1 |
| 20030013989 | Obermiller et al. | Jan 2003 | A1 |
| 20030023316 | Brown et al. | Jan 2003 | A1 |
| 20030086975 | Ringeisen | May 2003 | A1 |
| 20030100954 | Schuldt-Hempe et al. | May 2003 | A1 |
| 20030114937 | Leatherbury et al. | Jun 2003 | A1 |
| 20030133967 | Ruszczak et al. | Jul 2003 | A1 |
| 20030212460 | Darois et al. | Nov 2003 | A1 |
| 20030225355 | Butler | Dec 2003 | A1 |
| 20030232746 | Lamberti et al. | Dec 2003 | A1 |
| 20040034373 | Schuldt-Hempe et al. | Feb 2004 | A1 |
| 20040054406 | Dubson et al. | Mar 2004 | A1 |
| 20040059356 | Gingras | Mar 2004 | A1 |
| 20040101546 | Gorman et al. | May 2004 | A1 |
| 20040138762 | Therin et al. | Jul 2004 | A1 |
| 20040172048 | Browning | Sep 2004 | A1 |
| 20040215219 | Eldridge et al. | Oct 2004 | A1 |
| 20050002893 | Goldmann | Jan 2005 | A1 |
| 20050010306 | Priewe et al. | Jan 2005 | A1 |
| 20050021058 | Negro | Jan 2005 | A1 |
| 20050085924 | Darois et al. | Apr 2005 | A1 |
| 20050113849 | Popadiuk et al. | May 2005 | A1 |
| 20050113938 | Jamiolkowski et al. | May 2005 | A1 |
| 20050137512 | Campbell et al. | Jun 2005 | A1 |
| 20050142161 | Freeman et al. | Jun 2005 | A1 |
| 20050148963 | Brennan | Jul 2005 | A1 |
| 20050175659 | Macomber et al. | Aug 2005 | A1 |
| 20050228408 | Fricke et al. | Oct 2005 | A1 |
| 20050232979 | Shoshan | Oct 2005 | A1 |
| 20050244455 | Greenawalt | Nov 2005 | A1 |
| 20050267521 | Forsberg | Dec 2005 | A1 |
| 20050288691 | Leiboff | Dec 2005 | A1 |
| 20060094318 | Matsuda et al. | May 2006 | A1 |
| 20060135921 | Wiercinski et al. | Jun 2006 | A1 |
| 20060147501 | Hillas et al. | Jul 2006 | A1 |
| 20060167561 | Odar et al. | Jul 2006 | A1 |
| 20060216320 | Kitazono et al. | Sep 2006 | A1 |
| 20060252981 | Matsuda et al. | Nov 2006 | A1 |
| 20070031474 | Tayot | Feb 2007 | A1 |
| 20070161109 | Archibald et al. | Jul 2007 | A1 |
| 20070280990 | Stopek | Dec 2007 | A1 |
| 20070297987 | Stad et al. | Dec 2007 | A1 |
| 20070299538 | Roeber | Dec 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 1317836 | May 1993 | CA |
| 0 248 544 | Dec 1987 | EP |
| 0 276 890 | Aug 1988 | EP |
| 0 372 969 | Jun 1990 | EP |
| 0 544 485 | Jun 1993 | EP |
| 0552576 | Jul 1993 | EP |
| 0 614 650 | Sep 1994 | EP |
| 0621014 | Oct 1994 | EP |
| 0 625 891 | Nov 1994 | EP |
| 0 693 523 | Jan 1996 | EP |
| 0 705 878 | Apr 1996 | EP |
| 0 797 962 | Mar 1997 | EP |
| 0 774 240 | May 1997 | EP |
| 0 827 724 | Mar 1998 | EP |
| 0 895 762 | Feb 1999 | EP |
| 0 898 944 | Mar 1999 | EP |
| 0 637 452 | Oct 1999 | EP |
| 1 017 415 | Jul 2000 | EP |
| 1 052 319 | Nov 2000 | EP |
| 1 055 757 | Nov 2000 | EP |
| 1 216 717 | Jun 2002 | EP |
| 1 216 718 | Jun 2002 | EP |
| 1 315 468 | Jun 2003 | EP |
| 1382728 | Jan 2004 | EP |
| 1 484 070 | Dec 2004 | EP |
| 1 561 480 | Aug 2005 | EP |
| 1 782 848 | May 2007 | EP |
| 2244853 | Apr 1975 | FR |
| 2257262 | Aug 1975 | FR |
| 2453231 | Oct 1980 | FR |
| 2715405 | Jul 1995 | FR |
| 2744906 | Aug 1997 | FR |
| 2771622 | Jun 1999 | FR |
| 2779937 | Dec 1999 | FR |
| 2859624 | Mar 2005 | FR |
| 2863277 | Jun 2005 | FR |
| 2884706 | Oct 2006 | FR |
| 2 051 153 | Jan 1981 | GB |
| 03032677 | Feb 1991 | JP |
| 05237128 | Sep 1993 | JP |
| 09137380 | May 1997 | JP |
| WO 8902445 | Mar 1989 | WO |
| WO 8908467 | Sep 1989 | WO |
| WO 9012551 | Nov 1990 | WO |
| WO 9206639 | Apr 1992 | WO |
| WO 9220349 | Nov 1992 | WO |
| WO 9311805 | Jun 1993 | WO |
| WO 9318174 | Sep 1993 | WO |
| WO 9417747 | Aug 1994 | WO |
| WO 9507666 | Mar 1995 | WO |
| WO 9518638 | Jul 1995 | WO |
| WO 9532687 | Dec 1995 | WO |
| WO 9603091 | Feb 1996 | WO |
| WO 9608277 | Mar 1996 | WO |
| WO 9609795 | Apr 1996 | WO |
| WO 9614805 | May 1996 | WO |
| WO 9641588 | Dec 1996 | WO |
| WO 9735533 | Oct 1997 | WO |
| WO 9835632 | Aug 1998 | WO |
| WO 9849967 | Nov 1998 | WO |
| WO 9905990 | Feb 1999 | WO |
| WO 9906080 | Feb 1999 | WO |
| WO 9906079 | Feb 1999 | WO |
| WO 9951163 | Oct 1999 | WO |
| WO 0016821 | Mar 2000 | WO |
| WO0067663 | Nov 2000 | WO |
| WO 0115625 | Mar 2001 | WO |
| WO 0180773 | Nov 2001 | WO |
| WO 0207648 | Jan 2002 | WO |
| WO 02078568 | Oct 2002 | WO |
| WO 03002168 | Jan 2003 | WO |
| WO 2004004600 | Jan 2004 | WO |
| WO2004071349 | Aug 2004 | WO |
| WO 2004078120 | Sep 2004 | WO |
| WO2004103212 | Dec 2004 | WO |
| WO 2005013863 | Feb 2005 | WO |
| WO 2005018698 | Mar 2005 | WO |
| WO 2005105172 | Nov 2005 | WO |
| WO 200511280 | Dec 2005 | WO |
| WO 2006018552 | Feb 2006 | WO |
| WO 2006023444 | Mar 2006 | WO |
| WO 2007048099 | Apr 2007 | WO |
| Entry |
|---|
| Ellouali M, et al., “Antitumor activity of low molecular weight fucans extracted from brown seaweed Ascophyllum Nodosum”, Anticancer Res. Nov.-Dec. 1993; 12(6A):2011-9. |
| Malette et al., Chitosan, a new hemostatic, Ann Th. Surg. 1983, 36:55-58. |
| Langenbech Mr, et al., “Comparison of biomaterials in the early postoperative period”, Surg Endosc. 2003; 17(7):1105-9. |
| Bracco P., et al., “Comparison of polypropylene and polyethylene terephthalate (Dacron) meshes for abdominal wall hernia repair: a chemical and morphological study”, Hernia 2005, 9(1):51-55. |
| Klinge U, et al., “Foreign body reaction to meshes used for the repair of abdominal wall hernias”, Eur J. Surg 1999; 165:665-73. |
| Logeart D, et al., “Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect,” Eur J Cell Biol. Dec. 1997; 74(4):385-90. |
| Haneji K, et al.., “Fucoidan extracted from Cladosiphon Okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells”, Nutrition and Cancer, 2005; 52(2):189-201. |
| Junge K, et al., “Functional and morphologic properties of a modified mesh for inguinal hernia repair”, World J Surg 2002; 26:1472-80. |
| Klinge, et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair”, J. Biomed Mater Res 2002 63:129-136. |
| Welty G, et al., “Functional impairment and complaints following incisional hernia repair with different polypropylene meshes”, Hernia 2001;5:142-7. |
| Varum Km et al., “In vitro degradation rates of partially N-acetylated chitosans in human serum”, Carbohydrate Research, 1997, 299:99-101. |
| Haroun-Bouhedja F, et al., “In vitro effects of fucans on MDA-MB231 tumor cell adhesion and invasion”, Anticancer Res. Jul.-Aug. 2002;22(4):2285-92. |
| Scheidbach H, et al., “In vivo studies comparing the biocompatibility of various polypropylene meshes and their handling properties during endoscopic total extraperitoneal (TEP) patchplasty: an experimental study in pigs”, Surg Endosc 2004; 18(2):211-20. |
| Blondin C, et al., “Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed”, Molecular Immuol. Mar. 1994; 31(4):247-53. |
| Zvyagintseva Tn, et al., “Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds”, Comparative Biochem and Physiol Jul. 2000; 126(3):209-15. |
| Rosen M, et al., “Laparoscopic component separation in the single-stage treatment of infected abdominal wall prosthetic removal”, Hernia, 2007 11:435-440. |
| Amid P.K., “Lichtenstein tension-free hernioplasty: Its inception, evolution, and principles”, Hernia 2004; 8:1-7. |
| Boisson-Vidal C, et al., “Neoangiogenesis induced by progenitor endothelial cells: effect of fucoidan from marine algae”, Cardiovascular & Hematological Agents in Medicinal Chem. Jan. 2007; 5(1):67-77. |
| O'Dwyer Pj, et al., :Randomized clinical trial assessing impact of a lightweight or heavyweight mesh on chronic pain after inguinal hernia repair, Br J Surg. 2005; 92(2):166-70. |
| Muzzarelli, et al., “Reconstruction of parodontal tissue with chitosan”, Biomatetials 1989, 10:598-604. |
| Haroun-Bouhedja F, et al., “Relationship between sulfate groups and biological activities of fucans”, Thrombosis Res. Dec. 1, 2000, 100(5):453-9. |
| Blondin C, et al., “Relationships between chemical characteristics and anticomplementary activity of fucans”, Biomaterials. Mar. 1996; 17(6):597-603. |
| Strand Sp, et al., “Screening of chitosans and conditions for bacterial flocculation”, Biomacromolecules, 2001, 2:126-133. |
| Kanabar V, et al., “Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle”, Br J Pharmacol. Oct. 2005; 146(3):307-7. |
| Hirano et al., “The blood biocompatibility of chitosan and N-acylchitosans”, J Biomed. Mater. Res. 1985, 19:413-417. |
| Rao S.B., et al., “Use of chitosan as a biomaterial: studies on its safety and haemostatic potential”, J. Biomed. Mater. Res. 1997, 34:21-28. |
| Prokop A, et al., “Water soluble polymers for immunoisolation I: complex coacevation and cytotoxicity”, Advances in Polymer Science, 1998 136:1-51. |
| Collins et al., “Use of collagen film as a dural substitute: Preliminary Animal Studies”, Journal of Biomedical Materials Research, vol. 25, pp. 267-276(1991). |
| Preliminary Search Report from French Patent Office dated Dec. 20, 2006. |
| International Search Report for PCTIB08003761 date of completion is May 20, 2009 (3 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20090192532 A1 | Jul 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61005131 | Dec 2007 | US |
